Therapeutic Confirmatory (Phase III)

3,259 trials 1,319 recruiting

Filter these 3,259 trials by condition, country, sponsor and more.

Open in Search →

A clinical study to evaluate safety and efficacy of Caribasmate Ended

2023-506616-41-00 Lennox-Gastaut syndrome (LGS) 2023-03-31
A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex… Ended

2024-513462-19-00 Refractory Chronic Cough, Including Unexplained Chronic 2023-03-30
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended

2023-503444-13-00 Relapsed/refractory multiple myeloma 2023-03-29
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une… Ended

2024-513460-26-00 Refractory Chronic Cough, Including Unexplained Chronic 2023-03-29
A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c… Ended

2024-511169-12-00 Non-Small Cell Lung Cancer 2023-03-28
(Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors Ended

2022-500637-80-00 gastrointestinal stromal tumor 2023-03-28
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 2023-03-23
"Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizures " Ended

2023-506841-52-00 partial-onset (focal) seizures 2023-03-22
A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen… Ended

2024-512890-28-00 Primary immune thrombocytopenia (ITP) 2023-03-20
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab versus Placebo Administered Intravenously (IV) in Adult Participants With … Ended

2023-508350-26-00 Fibrodysplasia Ossificans Progressiva 2023-03-02
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 2023-02-28
A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended

2022-500138-27-01 Multiple Myeloma 2023-02-28
A Study to Determine the Effect of Triheptanoin Compared with Even-chain MCT on MCEs in Pediatric Patients with LC-FAOD Ended

2023-509809-76-00 Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) 2023-02-28
A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended

2024-514173-22-00 Cystic Fibrosis 2023-02-28
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… Ended

2023-505552-22-00 Stage I-III Triple-negative Breast Cancer with residual 2023-02-24
A study of ONCOFID-P-B administered intravesically to patients with Carcinoma in Situ of the bladder who have not responded to the standard … Ended

2024-512568-72-00 BCG-unresponsive Carcinoma in Situ of the bladder with 2023-02-24
A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L… Ended

2024-511594-30-00 Relapsed/Refractory Follicular Lymphoma 2023-02-23
A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely… Ended

2023-504719-34-00 Moderate to Severly Active Ulcerative Colitis 2023-02-21
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie… Ended

2022-501493-19-00 metastatic Castration-Resistant Prostate Cancer (mCRPC) 2023-02-20
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 2023-02-09
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Systemic Lupus Erythematosus 2023-02-03
A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o… Ended

2023-504277-20-00 Eosinophilic esophagitis (EoE) is a rare, chronic infla 2023-01-30
Multicenter, prospective, double-blind, randomized, three-armed, placebo-controlled study of long-term therapeutic transfer of encapsulated … Ended

2024-517132-22-00 active ulcerative colitis 2023-01-26
An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr… Ended

2024-510818-33-00 Chronic Spontaneous Urticaria 2023-01-24